|
Post by sportsrancho on Jul 7, 2017 13:08:35 GMT -5
AFREZZA, A INSULINA INALADA, FAZ PARCERIA E DEVE CHEGAR AO BRASIL Medicamento Notícia - 11 de junho de 2017 O novo CEO da ManKind, Michael Castagna ao lado de um modelo de inalador de Afrezza A empresa biofarmacêutica MannKind Corp. anunciou no final de maio uma mudança do seu alto executivo quando o CEO Matthew Pfeffer foi substituído por Michael Castagna, ex-diretor de operações da empresa. A MannKind tem sede em Valência, Califórnia, e também emprega cerca de 120 pessoas em sua fábrica de alta tecnologia em Danbury. A MannKind, fundada por Alfred E. Mann, fabrica e comercializa produtos terapêuticos comerciais para pacientes com doenças como diabetes. Seu principal produto é Afrezza, uma insulina de ação rápida para tratamento de diabetes. A Afrezza utiliza a tecnologia Technosphere da marca registrada da MannKind, que entrega medicamentos por inalação em vez de injeção. A plataforma Technosphere é o que “diferencia a empresa no mercado”, disse Castagna. No ano passado, a MannKind encerrou um acordo com a Sanofi, que falhou em sua tentativa de comercializar a Afrezza. MannKind agora fabrica, comercializa e vende Afrezza. Desenvolver um alcance mais amplo para Afrezza será o principal desafio de Castagna. Castagna, de 40 anos, visitou a instalação de Danbury na semana passada e discutiu com a Hearst Connecticut Media a direção que ele planeja dirigir a empresa, o futuro da MannKind em Danbury e uma variedade de outros tópicos relacionados à empresa. P: Onde você vê o MannKind no futuro? R: No curto prazo, nos próximos 12 a 18 a 24 meses, trata-se realmente de dar uma volta à Afrezza e garantir que esteja lá o máximo possível para ajudar as pessoas ao redor do mundo. À longo prazo, esperamos ter um pipeline de moléculas Technosphere que irá transformar a empresa. Nós somos predominantemente uma empresa dos EUA com nossa primeira aprovação (FDA); Agora estamos no processo de tomar essa aprovação e trazê-la para outros lugares do mundo. Nós temos uma fábrica aqui que é escalável e, para reduzir seus custos e tornar-se competitiva, você precisa ter uma escala de volume. A maneira como você obtém uma escala de volume é entrar nos mercados internacionais. Esse é um componente crítico à medida que avançamos. (Os EUA) crescerão ao longo do tempo, mas o volume, à curto prazo, pode vir de fora dos EUA. P: Você segmentou mercados internacionais específicos? R: Na semana passada, anunciamos uma parceria com o Brasil. Nós também estamos olhando para o Oriente Médio – como Emirados Árabes Unidos – como parte fundamental do mundo que, por razões culturais, preferiria uma insulina inalável por um injetável. Índia e China são dois mercados fantásticos. Há apenas uma pandemia acontecendo no mercado. A Índia tem 80 milhões de pessoas vivendo com diabetes. Isso, infelizmente, é uma doença de 30 a 40 anos. Os países em desenvolvimento estão realmente se preparando para um fardo de custo significativo em cuidar das pessoas no futuro. Hoje, eles não estão vendo muitos danos, mas nos próximos 10 anos eles verão muitos danos por não administrar seus açúcares. Quando você vê 80 milhões de pessoas em um país realmente em direção ao desastre, isso vai ter uma conseqüência significativa para a sociedade. P: Por que Afrezza lutou às vezes para ganhar força nos EUA? A: Toda vez que você está passando por uma mudança monumental em como você trata uma doença, leva tempo. Os médicos estão fazendo o mesmo por 30 ou 40 anos e, de repente, você está dizendo: “Pense na doença de forma diferente, pense na insulina de maneira diferente”. Isso simplesmente não acontece durante a noite. Trata-se de ensinar médicos como mudar seus comportamentos e usar a droga, porque uma vez que eles fazem eles não voltam. www.tiabeth.com/
|
|
|
Post by gamblerjag on Jul 7, 2017 13:43:12 GMT -5
que?
|
|
|
Post by mnholdem on Jul 7, 2017 13:48:50 GMT -5
With Google translator:
AFREZZA, THE INHALED INSULIN, MAKES PARTNERSHIP AND MUST COME TO BRAZIL Medication News - June 11, 2017
[Image]The new CEO of ManKind, Michael Castagna next to a model of Afrezza inhaler. The biopharmaceutical company MannKind Corp. announced in late May a change from its top executive when CEO Matthew Pfeffer was replaced by Michael Castagna, the company's former chief operating officer.
MannKind is based in Valencia, California, and also employs about 120 people in its high-tech factory in Danbury. MannKind, founded by Alfred E. Mann, manufactures and markets commercial therapeutic products for patients with diseases such as diabetes.
Its main product is Afrezza, a fast acting insulin for diabetes treatment. Afrezza uses Technosphere technology from MannKind's trademark, which delivers drugs through inhalation rather than injection. The Technosphere platform is what "differentiates the company in the market," said Castagna.
Last year, MannKind entered into an agreement with Sanofi, which failed to market Afrezza. MannKind now manufactures, markets and sells Afrezza. Developing a wider reach for Afrezza will be Castagna's main challenge.
Castagna, 40, visited the Danbury facility last week and discussed with Hearst Connecticut Media the direction he plans to run the company, the future of MannKind in Danbury, and a variety of other company-related topics.
Q: Where do you see MannKind in the future?
A: In the short term, over the next 12 to 18 to 24 months, it's really about taking a walk around Afrezza and making sure it's there as much as possible to help people around the world. In the long run, we expect to have a pipeline of Technosphere molecules that will transform the company.
We are predominantly a US company with our first approval (FDA); We are now in the process of taking this approval and bringing it to other places in the world. We have a factory here that is scalable and to reduce your costs and become competitive, you need to have a volume scale. The way you get a volume scale is to enter the international markets. This is a critical component as we move forward. (US) will grow over time, but the volume, in the short term, may come from outside the US.
Q: Did you target specific international markets?
A: Last week, we announced a partnership with Brazil. We are also looking at the Middle East - as the United Arab Emirates - as a fundamental part of the world that, for cultural reasons, would prefer an inhaled insulin for an injectable.
India and China are two fantastic markets. There is only one pandemic going on in the market. India has 80 million people living with diabetes. This, unfortunately, is a disease of 30 to 40 years. Developing countries are really preparing for a significant cost burden in caring for people in the future. Today, they are not seeing much damage, but in the next 10 years they will see many damages for not managing their sugars.
When you see 80 million people in a country really heading toward disaster, this will have a significant consequence for society.
Q: Why did Afrezza sometimes struggle to gain strength in the United States?
A: Every time you are undergoing a monumental change in how you treat an illness, it takes time. Doctors are doing the same for 30 or 40 years, and all of a sudden you're saying, "Think of the disease differently, think of insulin differently." It just does not happen overnight.
It is about teaching doctors how to change their behaviors and use the drug because once they do they do not come back.
|
|
|
Post by mango on Jul 7, 2017 14:15:10 GMT -5
The full article:
DANBURY — Biopharmaceutical company MannKind Corp. announced in late May a change of its top executive when CEO Matthew Pfeffer was replaced by Michael Castagna, the company’s former chief operating officer. Pfeffer had been with MannKind since 2008.
MannKind is based in Valencia, Calif., and also employs about 120 people at its high-tech manufacturing facility in Danbury. MannKind, which was founded by Alfred E. Mann, manufactures and markets commercial therapeutic products for patients with diseases such as diabetes.
Its main product is Afrezza, a fast-acting insulin for diabetes treatment. Afrezza utilizes MannKind’s trademarked Technosphere technology, which delivers drugs through inhalation instead of injection. The Technosphere platform is what “differentiates the company in the marketplace,” Castagna said.
Last year, MannKind terminated an agreement with Sanofi, which failed in its attempt to market Afrezza. MannKind now manufacturers, markets and sells Afrezza. Developing a broader reach for Afrezza will be Castagna’s primary challenge.
Castagna, 40, visited the Danbury facility last week and discussed with Hearst Connecticut Media the direction he plans to steer the company, MannKind’s future in Danbury and a variety of other topics relating to the company.
Q: Where do you see MannKind going in the future?
A: In the near term, the next 12 to 18 to 24 months, it’s really about turning around Afrezza and making sure that it’s out there as much as possible to help people around the world. In the long run, we hope to have a pipeline of Technosphere molecules that will transform the company.
We are predominately a U.S. company with our first (FDA) approval; now we are in the process of taking that approval and bringing it to other places in the world. We have a factory here that’s scalable, and in order to get your costs down and become competitive, you have to have scale of volume. The way you get scale of volume is to get into international markets. That’s a critical component as we go forward. (The) U.S. will grow over time, but the volume, short term, can come from outside the U.S.
Q: Have you targeted any specific international markets?
A: Last week we announced a partnership with Brazil. We are also looking at the Middle East — such as United Arab Emirates — as a key part of the world that, for cultural reasons, would really prefer an inhalable insulin over an injectable.
India and China are two fantastic markets. There’s just a pandemic going on out there in the marketplace. India has 80 million people living with diabetes. This, unfortunately, is a 30- to 40-year disease. The developing countries are really setting themselves up for a significant cost burden in taking care of people in the future. Today, they are not seeing a lot of damage, but over the next 10 years they will see a lot of damage from not managing their sugars.
When you see 80 million people in a country really heading for disaster, that’s going to have a significant consequence for society.
Q: Why has Afrezza struggled at times to gain traction in the U.S.?
A: Any time you are undergoing a monumental shift in how you treat a disease, it takes time. Doctors have been doing the same thing for 30 or 40 years and then all of the sudden you are saying: “Think of the disease differently, think of insulin differently.” That just doesn’t happen overnight.
It’s about teaching doctors how to shift their behaviors and use the drug, because once they do they don’t go back.
Q: What other products are you developing?
A: We have several interesting pipeline candidates. It’s about prioritization. You look at epinephrine. That was a big debate because of drug pricing. We know we can make epinephrine at a reasonable cost and reasonable ability to use. Personally, I think that can be a nice drug to get to the market in a reasonable time frame. We have the (Technosphere) technology and it’s proven, so our time to develop a new drug is much faster.
To carry a little disposable epinephrine in your pocketbook or something is much easier than carrying a big pen around with you. I’m excited about that product. This could make a big difference for patients. We’re looking at either potential partners to bring that forward, or we’ll fund that ourselves.
We have couple other molecules we’re looking at: chemotherapy, PTH (Parathyroid hormone) and a couple other molecules we’re looking at for different diseases that have real potential to make it to market.
The other way we transform the company is looking for additional assets to acquire. How do we bring in more molecules to the company? It’s expensive to have a sales force so if you can put in another product or two for that sales force that brings more stability and diversity to the company.
Q: A change at the top of an organization often brings other changes. What is the company’s future in Danbury and Connecticut?
A: In general, you don’t move manufacturing plants. Once they are in the ground they usually stay. To move it would take years. So, from my perspective, we plan to have the facility here producing Afrezza for the long term.
The technology is here, the labs are here, the talent is here, so I don’t see a monumental shift in our operations. I have no intention of bringing this facility to California. It’s a beautiful facility here and we have lots of space here, as well. So as we grow it will be interesting to see where we put certain back-end office jobs. For example, if I wanted to have a patient-care call center, we can put 30 to 50 people in that call center easily. Would I put that in California or would I put that in Danbury? Those are the types of questions that come up when you grow. It’s never been a question of moving everyone to California.
California has its own job challenges and high taxes. I think it’s worse than Connecticut, to be honest. It’s close.
The good news is, there seems to be, over the last decade, a little biotech and innovation culture in Connecticut. Innovation is critical. Companies that don’t reinvent themselves don’t stay relevant. If you don’t stay relevant you won’t stay around long for your employees. That’s our job as a management team: To keep the company relevant and transform ourselves to be competitive, but also be a different pharmaceutical company.
|
|
|
Post by mnkdfann on Jul 7, 2017 15:01:36 GMT -5
AFREZZA, A INSULINA INALADA, FAZ PARCERIA E DEVE CHEGAR AO BRASIL Medicamento Notícia - 11 de junho de 2017 O novo CEO da ManKind, Michael Castagna ao lado de um modelo de inalador de Afrezza A empresa biofarmacêutica MannKind Corp. anunciou no final de maio uma mudança do seu alto executivo quando o CEO Matthew Pfeffer foi substituído por Michael Castagna, ex-diretor de operações da empresa. I believe the same article / interview originated in English, and was posted on this site last month. Here is (I think) the original. www.newstimes.com/business/article/New-MannKind-CEO-Afrezza-global-markets-are-key-11208232.php
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 7, 2017 15:26:53 GMT -5
Sports stop being so quick on the trigger. read it first
|
|
|
Post by MnkdWASmyRtrmntPlan on Jul 7, 2017 15:59:43 GMT -5
Humph, Mike portrays the appearance of not having a single financial care in the world. Oh, to be a fly on the wall of his brain. Good find, Sports.
|
|
|
Post by mnholdem on Jul 7, 2017 18:39:27 GMT -5
Sports stop being so quick on the trigger. read it first When you decide to practice what you preach, you'll be less likely to put your foot in your mouth. This article was published at TiaBeth.com, an online publication in Rio de Janeiro, Brazil. Learning that this article was headlined in an online health mag for Brazilians makes it news to shareholders, IMHO.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 8, 2017 9:44:21 GMT -5
Sports stop being so quick on the trigger. read it first When you decide to practice what you preach, you'll be less likely to put your foot in your mouth. This article was published at TiaBeth.com, an online publication in Rio de Janeiro, Brazil. Learning that this article was headlined in an online health mag for Brazilians makes it news to shareholders, IMHO. That's funny. Especially coming from the King of putting their foot in their mouth. Tell me MNHOLDEM when have you actually gotten a MNKD call correct? This is far from news. That is a stretch but its par for the course with you
|
|
|
Post by brotherm1 on Jul 8, 2017 11:14:43 GMT -5
When you decide to practice what you preach, you'll be less likely to put your foot in your mouth. This article was published at TiaBeth.com, an online publication in Rio de Janeiro, Brazil. Learning that this article was headlined in an online health mag for Brazilians makes it news to shareholders, IMHO. That's funny. Especially coming from the King of putting their foot in their mouth. Tell me MNHOLDEM when have you actually gotten a MNKD call correct? This is far from news. That is a stretch but its par for the course with you I don't ever recall him being incorrect or putting his foot in his mouth, as you say, and certainly never to the point of being the "King" of it. What exactly are you referring to?
|
|
|
Post by mnholdem on Jul 8, 2017 11:49:28 GMT -5
When you decide to practice what you preach, you'll be less likely to put your foot in your mouth. This article was published at TiaBeth.com, an online publication in Rio de Janeiro, Brazil. Learning that this article was headlined in an online health mag for Brazilians makes it news to shareholders, IMHO. That's funny. Especially coming from the King of putting their foot in their mouth. Tell me MNHOLDEM when have you actually gotten a MNKD call correct? This is far from news. That is a stretch but its par for the course with you I don't make "calls" anymore and haven't for quite some time, unless you consider informational posts provided with links - including some from MNKD's Investor Relations department - to somehow be predictions.
|
|
|
Post by mnkdfann on Jul 8, 2017 13:26:10 GMT -5
Sports stop being so quick on the trigger. read it first When you decide to practice what you preach, you'll be less likely to put your foot in your mouth. This article was published at TiaBeth.com, an online publication in Rio de Janeiro, Brazil. Learning that this article was headlined in an online health mag for Brazilians makes it news to shareholders, IMHO. Hate to be a complainer, but none of the information about how the "article was headlined in an online health mag for Brazilians" was apparent in the OP. Clicking the link took one to a foreign language website. In Portuguese, I assume? Based who knows where (it could be a Portuguese-American blog site based in NYC for all I know). How many of us here read Portuguese? And even if one did, the Mannkind interview may or may not have been visible (as the headlines there rotate across several stories at any given time, so maybe it depends on when you click and how long you watch whether you even see it or not). To me, it seemed someone was just reposting an old, random Mannkind story (something that happens here rather frequently), unaware that it was previously published in English and previously posted on this forum. Anyway, sorry to interrupt you two.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 8, 2017 13:44:06 GMT -5
That's funny. Especially coming from the King of putting their foot in their mouth. Tell me MNHOLDEM when have you actually gotten a MNKD call correct? This is far from news. That is a stretch but its par for the course with you I don't make "calls" anymore and haven't for quite some time, unless you consider informational posts provided with links - including some from MNKD's Investor Relations department - to somehow be predictions. I am glad you have learned from your mistakes and got tired of being wrong.
|
|
|
Post by sportsrancho on Jul 8, 2017 15:43:33 GMT -5
I don't make "calls" anymore and haven't for quite some time, unless you consider informational posts provided with links - including some from MNKD's Investor Relations department - to somehow be predictions. I am glad you have learned from your mistakes and got tired of being wrong. My mistake, no one else's.
|
|
|
Post by mnholdem on Jul 8, 2017 16:48:25 GMT -5
3-4 weeks ago, Brazilians were introduced to MannKind Corporation and a recent interview with its new CEO. How is that a mistake? Afrezza is coming to Brazil. Sports, you were the only one here on ProBoards who noticed and posted about it. You even provided a link, which I checked and others could also have done before criticizing your post.
There's no mistake. This is relevant news regardless of whether TiaBeth used excerpts from the Castagna interview in their article.
Thank you!
|
|